NOVEL THERAPY FOR TREATMENT OF HEMOGLOBINOPATHIES (BETA-THALASSEMIA AND SICKLE CELL DISEASE)
Thalassemias are the result of the most common single gene genetic disorder worldwide, affecting 30 out of every 1000 people. Spanning from mild to life-threatening manifestations due to its autosomal recessive genetic inheritance, beta-thalassemia is caused by mutations in the y-globin gene. …
PLATELET-DERIVED GROWTH FACTOR RECEPTOR BETA AND NOTCH3 RECEPTOR MODULATORS FOR THE TREATMENT OF INFANTILE MYOFIBROMATOSIS
Infantile myofibromatosis (IMF) is one of the most common proliferative fibrous tumors of infancy and childhood. IMF is a disorder of mesenchymal proliferation characterized by the development of non-metastasizing tumors in the skin, muscle, bone and viscera. Occurrence within families across multiple …
NOVEL MICRO-RNA THERAPY FOR TREATMENT OF DRAVET SYNDROME, A PEDIATRIC ORPHAN DISEASE
Dravet syndrome (DS), also known as severe myoclonic epilepsy of infancy (SMEI), is a genetic and rare form of treatment-refractory epilepsy that begins in infancy. DS incidence is estimated at 1/30,000 with about 20,000-40,000 patients worldwide. The long-term prognosis for DS patients …
USE OF FLUOXETINE TO TREAT AUTISM SPECTRUM DISORDER
Autism spectrum disorder (ASD) is a collection of development disorders characterized by difficulties in social interaction, verbal and nonverbal communication and repetitive behaviors. In addition to social deficits, ASD can also result in intellectual delays, irritability, problems with motor coordination, and additional …
USE OF MEMANTINE TO TREAT AUTISM AND ASSOCIATED DISORDERS
Autism spectrum disorder (ASD) is a collection of development disorders of unknown etiology characterized by difficulties in social interaction, verbal and nonverbal communication and repetitive behaviors. In addition to social deficits, ASD can also result in intellectual delays, irritability, problems with motor coordination, …
NOVEL THERAPY TO REDUCE SUICIDAL IDEATION ASSOCIATED WITH SSRI USE
Major Depressive Disorder (depression) is a mental disorder with symptoms including low mood, low self-esteem and loss of pleasure. Approximately 14.8 million patients in the US are affected by depression. Selective Serotonin Reuptake Inhibitors (SSRIs) are commonly used in patients to treat depression, as …
Technology Transfer: Commercialization and Innovation Infographic
by AvalancheInfographics. Explore more visuals like this one on the web’s largest information design community – Visually. …
Intranasal Ketamine Confers Rapid Antidepressant Effect in Depression
April 8, 2014 – A research team from the Icahn School of Medicine at Mount Sinai published the first controlled evidence showing that an intranasal ketamine spray conferred an unusually rapid antidepressant effect –within 24 hours—and was well tolerated in patients with treatment-resistant major …
Harrington Scholar-Innovator Grant Program
The Harrington Scholar-Innovator Award recognizes physician-scientists throughout the U.S. whose research has the potential to change standard of care. The Award provides clinical research funding as well as non-financial support to selected investigators and their institutions to help bridge the gap between …
Erik Lium, PhD, Named Vice President of Mount Sinai Innovation Partners
March 31, 2014 – Erik Lium, PhD, a 16-year veteran with an extensive background in the academic, technology and medical sectors, has been named Vice President and Executive Director of Mount Sinai Innovation Partners, which facilitates the real-world application and commercialization of Mount Sinai …